Lyka Labs Ltd - 500259 - Financial Results For The Fourth Quarter And Financial Year Ended 31 March, 2021
Financial Results for the Fourth Quarter and Financial year ended 31 March, 202102-06-2021
02-06-2021
Lyka Labs Ltd - 500259 - Outcome Of Board Meeting
Outcome of Board Meeting. Meeting Commenced at 04. 00 P.M and Meeting Concluded at 04.46 P.M.02-06-2021
Lyka Labs Ltd - 500259 - Board Meeting Intimation for Consideration Of Audited Financial Results
LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2021 ,inter alia, to consider and approve We wish to inform you that as per Regulation 29 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, a Meeting of Board of Directors of the Company is convened on Wednesday, 02 June, 2021, to consider inter alia the following businesses: 1. To consider, approve and adopt Standalone Audited Financial Results for the Fourth Quarter and Financial Year ended 31 March, 2021; 2. To consider, approve and adopt Consolidated Audited Financial Results for the Fourth Quarter and Financial Year ended 31 March, 2021. As informed earlier the Trading window is closed from 01April, 2021 till 48 hours after declaration of Audited Financial Results for the Fourth quarter and Financial year ended 31 March 2021. Kindly take the same on your record.26-05-2021
Lyka Labs Ltd - 500259 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
We wish to inform you that there is a false message being circulated on various social media platforms including WhatsApp, misleading the public into believing that our company is having stock of Remdesivir Injection (medicine used for treatment of COVID - 19 patients) and that the same can be purchased from our office at Spencer Building, Forjett Street; Tardeo, Grant Road, Mumbai 400 036. We would like to clarify that we only manufacture Remdesivir Injection on a contractual basis for other companies which place orders with our company. We do not sell Remdesivir Injection directly to Wholesalers /Retailers /Hospitals /Institutions. This is submitted for information.19-04-2021
Lyka Labs Ltd - 500259 - Compliance Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosures Requirements) Regulation, 2015
In compliance with Regulation 40(9) of SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015, we enclose herewith a copy of Compliance Certificate dated 15 April, 2021 issued by Kaushal Doshi & Associates, practicing Company Secretaries for the half year ended 31 March, 2021.16-04-2021
LYKA LABS LTD. - 500259 - Shareholding for the Period Ended March 31, 2021
Lyka Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here14-04-2021
LYKA LABS LTD. - 500259 - Confirmation Regarding Non Applicability Of SEBI Circular Dated 26 November, 2018
Pursuant to SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 144 dated 26 November, 2018, regarding fund raising by issuance of Debt Securities by Large Entity and disclosure and compliance thereof by such Large Corporate (LC), we, Lyka Labs limited hereby confirm that all the conditions mentioned in clause 2.2 of aforesaid Circular pertaining to the Large Corporate (LC) category are not applicable to our Company. This is for your information and record.12-04-2021
LYKA LABS LTD. - 500259 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 please find enclosed Certificate for the quarter ended 31 March, 2021 received form M/s Link Intime India Pvt Ltd, Registrar and Share Transfer Agent of the Company.12-04-2021
LYKA LABS LTD. - 500259 - Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (Listing Obligation And Disclosure Requirements), 2015 For Half Year Ended 31 March, 2021
Pursuant to Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Compliance Certificate, duly signed by Authorized Signatory of M/s. Link Intime India Pvt Ltd, Share Transfer Agent of the Company and by the Company Secretary and Compliance Officer of the Company for the half year ended 31 March, 202112-04-2021